1.Fiore AE., Uyeki TM., Broder K., Finelli L., Euler GL., Singleton JA, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010. 59:1–62.
2.Korean Centers for Disease Control & Prevention. Weekly Sentinel Surveillance Report. http://www.cdc.go.kr/CDC/info/CdcKrInfo0402.jsp?menuIds=HOME001-MNU1132-MNU1138-MNU 0045/. [Online] (last visited on 31 December 2014).
3.Thompson WW., Shay DK., Weintraub E., Brammer L., Bridges CB., Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004. 292:1333–40.
Article
4.Wie SH., So BH., Song JY., Cheong HJ., Seo YB., Choi SH, et al. A comparison of the clinical and epidemiological characteristics of adult patients with laboratory-confirmed influenza A or B during the 2011-2012 influenza season in Korea: a multi-center study. PLoS One. 2013. 8:e62685.
Article
5.Kumar S., Henrickson KJ. Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic. Clin Microbiol Rev. 2012. 25:344–61.
Article
6.BD Diagnostics. BD Veritor System for Rapid Detection of Flu A+B. Spark, MD; BD Diagnostics. 2014.
7.Hwang Y., Kim K., Lee M. Evaluation of the efficacies of rapid antigen test, multiplex PCR, and real-time PCR for the detection of a novel influenza A (H1N1) virus. Korean J Lab Med. 2010. 30:147–52.
Article
8.Chartrand C., Leeflang MM., Minion J., Brewer T., Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med. 2012. 156:500–11.
9.Hassan F., Nguyen A., Formanek A., Bell JJ., Selvarangan R. Comparison of the BD Veritor System for Flu A+B with the Alere BinaxNOW influenza A&B card for detection of influenza A and B viruses in respiratory specimens from pediatric patients. J Clin Microbiol. 2014. 52:906–10.
10.Nam MH., Jang JW., Lee JH., Cho CH., Lim CS., Kim WJ. Clinical performance evaluation of the BD Veritor System Flu A+B assay. J Virol Methods. 2014. 204:86–90.
Article
11.Kwon D., Shin K., Kwon M., Oh HB., Kang C., Lee JY. Deve-lopment and evaluation of a rapid influenza diagnostic test for the pandemic (H1N1) 2009 influenza virus. J Clin Microbiol. 2011. 49:437–8.
Article
12.Korean Centers for Disease Control & Prevention. Public Health Weekly Report. Rapid diagnostic tests for influenza.http://www.cdc.go.kr/CDC/contents/CdcKrContentLink.jsp?fid.=31&cid=12744&ctype=6/. [Online] (last visited on 23 January 2015).
13.LG Life Sciences. AdvanSure RV real-time PCR. Seoul, Korea: LG Life Sciences;2013.
14.Fiore AE., Fry A., Shay D., Gubareva L., Bresee JS., Uyeki TM. Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011. 60:1–24.
15.Carrat F., Vergu E., Ferguson NM., Lemaitre M., Cauchemez S., Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008. 167:775–85.
Article
16.Ginocchio CC., Zhang F., Manji R., Arora S., Bornfreund M., Falk L, et al. Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York City outbreak. J Clin Virol. 2009. 45:191–5.
Article
17.Monto AS., Gravenstein S., Elliott M., Colopy M., Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000. 160:3243–7.
Article
18.Hsu J., Santesso N., Mustafa R., Brozek J., Chen YL., Hopkins JP, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012. 156:512–24.
19.Muthuri SG., Myles PR., Venkatesan S., Leonardi-Bee J., Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A (H1N1) pandemic: a systematic review and meta- analysis in hospitalized patients. J Infect Dis. 2013. 207:553–63.